CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore the safety and efficacy of CNCT19 (a
second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by
Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory
B-cell lymphoma.